Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has received an average rating of “Hold” from the six analysts that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $6.25.
CPRX has been the topic of a number of analyst reports. Zacks Investment Research cut Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. BidaskClub cut Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, January 24th. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, November 10th. Roth Capital set a $5.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Finally, Piper Jaffray Companies set a $8.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 1st.
Shares of Catalyst Pharmaceuticals (NASDAQ CPRX) traded down $0.15 on Friday, hitting $3.47. The stock had a trading volume of 623,033 shares, compared to its average volume of 537,955. Catalyst Pharmaceuticals has a 12-month low of $1.03 and a 12-month high of $4.51. The company has a market cap of $370.96, a PE ratio of -16.52 and a beta of 1.68.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. research analysts forecast that Catalyst Pharmaceuticals will post -0.22 earnings per share for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in the stock. OxFORD Asset Management LLP lifted its position in Catalyst Pharmaceuticals by 46.2% in the 2nd quarter. OxFORD Asset Management LLP now owns 86,168 shares of the biopharmaceutical company’s stock valued at $238,000 after acquiring an additional 27,228 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in Catalyst Pharmaceuticals by 23.4% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 148,704 shares of the biopharmaceutical company’s stock valued at $582,000 after acquiring an additional 28,204 shares in the last quarter. Nationwide Fund Advisors bought a new position in Catalyst Pharmaceuticals in the 2nd quarter valued at approximately $111,000. New York State Common Retirement Fund bought a new position in Catalyst Pharmaceuticals in the 2nd quarter valued at approximately $114,000. Finally, SG Americas Securities LLC bought a new position in Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $144,000. 34.89% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This article was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/29/catalyst-pharmaceuticals-inc-cprx-receives-6-25-average-pt-from-analysts.html.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.